Menu

研究業績Publications

最近(過去5年程度)の代表論文

  1. Karaki T, Inoue W, Gis T, Shichinohe S, Watanabe T, Hirai T, Yoshioka Y(コレスポンディングオーサー). Rationally designed negatively charged lipid nanoparticles reduce systemic reactogenicity of mRNA vaccines while preserving immunogenicity. J Control Release. 2026 Oct 24:115490.
  2. Hirata H, Abe Y, Itoh Y, Hirai T, Yoshioka Y(コレスポンディングオーサー). Enhancing mRNA-lipid nanoparticle vaccine-induced T cell responses by simple supplementation with class B CpG oligodeoxynucleotides. Int J Pharm. 2026 Oct 26:127604.
  3. Senpuku K, Kunishima Y, Hirose M, Karaki T, Taniguchi K, Kataoka-Nakamura C, Hirai T, Yasuda K, Kuroda E, Kato T, Ito T, Yoshioka Y(コレスポンディングオーサー). Comparative immunogenic and structural analysis of virus-like particle and inactivated whole-virion vaccines against enterovirus D68. Mol Ther Nucleic Acids.  2026 Apr 1;34(4):2496-2512.
  4. Honda K, Karaki T, Kunishima Y, Kawaguchi Y, Takemura N, Matsuzaki T, Fukada SI, Saitoh T, Yoshioka Y(コレスポンディングオーサー). Inflammatory mediators of mRNA vaccine-induced adverse reactions in mice. Mol Ther.  2026 Apr 1;34(4):2496-2512.
  5. Kunishima Y, Senpku K, Kataoka-Nakamura C, Hirai T, Yoshioka Y(コレスポンディングオーサー). mRNA vaccine expressing enterovirus D68 virus-like particles induces potent neutralizing antibodies and protects against infection. Mol Ther Nucleic Acids. 2025 Oct 6;36(4):102731.
  6. Kawaguchi Y, Kimura M, Karaki T, Tanaka H, Ono C, Ishida T, Matsuura Y, Hirai T, Akita H, Shimizu T, Yoshioka Y(コレスポンディングオーサー). Modulating Immunogenicity and Reactogenicity in mRNA-Lipid Nanoparticle Vaccines through Lipid Component Optimization. ACS Nano. 2025 Aug 5;19(30):27977-28001.
  7. Hashimoto S, Hirai T, Ueda K, Kakihara M, Tokunoh N, Ono C, Matsuura Y, Takayama K, Yoshioka Y(コレスポンディングオーサー). Hypertonic intranasal vaccines gain nasal epithelia access to exert strong immunogenicity. Mucosal Immunol. 2025 Aug;18(4):793-809.
  8. Kawai A, Shimizu T, Tanaka H, Shichinohe S, Anindita J, Hirose M, Kawahara E, Senpuku K, Shimooka M, Quynh Mai LT, Suzuki R, Nogimori T, Yamamoto T, Hirai T, Kato T, Watanabe T, Akita H, Yoshioka Y(コレスポンディングオーサー). Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions. Mol Ther. 2025 Feb 5;33(2):529-547.
  9. Kawahara E, Senpuku K, Kawaguchi Y, Yamamoto S, Yasuda K, Kuroda E, Ouji-Sageshima N, Ito T, Hirai T, Shibata T, Yoshioka Y(コレスポンディングオーサー). Recombinant RSV G protein vaccine induces enhanced respiratory disease via IL-13 and mucin overproduction. NPJ Vaccines. 2024 Oct 12;9(1):187.
  10. Kawai A, Noda M, Hirata H, Munakata L, Matsuda T, Omata D, Takemura N, Onoe S, Hirose M, Kato T, Saitoh T, Hirai T, Suzuki R, Yoshioka Y(コレスポンディングオーサー). Lipid Nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a Component Lipid Confers Potent Responses of Th1 Cells and Antibody against Vaccine Antigen. ACS Nano. 2024 Jul 2;18(26):16589-16609.
  11. Kawai A, Tokunoh N, Kawahara E, Tamiya S, Okamura S, Ono C, Anindita J, Tanaka H, Akita H, Yamasaki S, Kunisawa J, Okamoto T, Matsuura Y, Hirai T, Yoshioka Y(コレスポンディングオーサー). Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses. J Clin Invest. 2023 Dec 1;133(23):e166827.
  12. Morita M, Yoneda A, Tokunoh N, Masaki T, Shirakura K, Kinoshita M, Hashimoto R, Shigesada N, Takahashi J, Tachibana M, Tanaka S, Obana M, Hino N, Ikawa M, Tsujikawa K, Ono C, Matsuura Y, Kidoya H, Takakura N, Kubota Y, Doi T, Takayama K, Yoshioka Y, Fujio Y, Okada Y. Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models. Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2213317120.
  13. Hashimoto R, Takahashi J, Shirakura K, Funatsu R, Kosugi K, Deguchi S, Yamamoto M, Tsunoda Y, Morita M, Muraoka K, Tanaka M, Kanbara T, Tanaka S, Tamiya S, Tokunoh N, Kawai A, Ikawa M, Ono C, Tachibana K, Kondoh M, Obana M, Matsuura Y, Ohsumi A, Noda T, Yamamoto T, Yoshioka Y, Torisawa YS, Date H, Fujio Y, Nagao M, Takayama K, Okada Y. SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression. Sci Adv. 2022 Sep 23;8(38):eabo6783.
  14. Kitagawa S, Matsuda T, Washizaki A, Murakami A, Yamamoto T, Yoshioka Y(コレスポンディングオーサー). Elucidation of the role of nucleolin as a cell surface receptor for nucleic acid-based adjuvants. NPJ Vaccines. 2022 Oct 6;7(1):115.
  15. Matsuda T, Misato K, Tamiya S, Akeda Y, Nakase I, Kuroda E, Takahama S, Nonaka M, Yamamoto T, Fukuda MN, Yoshioka Y(コレスポンディングオーサー). Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice. iScience. 2022 Oct 10;25(11):105324.